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Abstract
Transcatheter aortic valve replacement in the setting of failed surgical bioprosthesis (valve-in-valve) is a valuable option
for patients with bioprosthetic aortic stenosis or regurgitation who are deemed high risk for repeat open heart surgery.
Although the procedure is successful with proper preprocedural assessment, instances of left main (LM) coronary artery
ostium obstruction have been documented. We present a case of LM coronary obstruction in the immediate postoperative
period following implantation of a 20-mm Edwards Sapien 3 valve inside the degenerated 21-mm Mitroflow bioprosthesis
stenosis, which was treated with double stenting alongside the Edwards Sapien 3 valve creating a channel (“neo left main”)
that extended from mid-LM to the upper margin of the Edwards Sapien 3 valve. Although valve-in-valve in a Mitroflow
degenerated bioprosthesis is a relatively safe procedure, 2 or more stents may be necessary to scaffold a channel to the
coronary arteries between Edwards Sapien 3 prosthesis and aorta in the event of a coronary obstruction.
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Introduction

Case Description

With the advancement in technology, transcatheter aortic
valve replacement (TAVR) for failed surgical aortic bioprosthesis (valve-in-valve [VIV]) has become a widely
accepted option for patients at high risk for redo open heart
surgery.1 The TAVR procedure is successful in the majority
of patients, though coronary ostial obstruction has been
reported as one of the most serious complications associated with high mortality.1-5 Data suggest that insertion of
Edwards Sapien 3 valve in VIV procedure is not associated
with coronary obstruction.6-10 We reported the first case of
left main (LM) coronary ostium obstruction following
insertion of Edwards Sapien 3 valve on degenerated
Mitroflow aortic bioprosthesis stenosis, successfully
treated with the insertion of 2 bare metal stents creating a
channel between Edwards Sapien 3 valve and aorta toward
LM coronary artery ostium.

An 81-year-old female presented with increasing shortness of
breath with exertion for about 1 year. Past surgical history
was significant for aortic valve replacement using a 21-mm
Mitroflow bioprosthesis for aortic stenosis and coronary
artery bypass surgery with a left internal mammary artery
1

University of North Dakota, Fargo, ND, USA
East Tennessee State University, Johnson City, TN, USA
3
University of Nebraska Medical Center, Omaha, NE, USA
2

Received November 8, 2017. Revised March 2, 2018. Accepted March 4,
2018.
Corresponding Author:
Timir Paul, MD, PhD, MPH, FACC, FSCAI, Division of Cardiology, East
Tennessee State University, 325 North State of Franklin Road, Johnson
City, TN 37614-0661, USA.
Email: pault@etsu.edu

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License
(http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

Figure 1. Transesophageal echocardiography guided
implantation of a 20-mm Edwards Sapien 3 valve inside a 21-mm
Mitroflow bioprosthesis.

graft to the left anterior descending artery 3 years before the
current presentation. Comorbidities included atrial fibrillation, obesity, hypertension, and hyperlipidemia. Physical
examination showed grade 3/6 systolic murmur in the right
second intercostal space. Echocardiography revealed severe
bioprosthetic stenosis with a mean transaortic gradient of 41
mm Hg and aortic valve orifice of 0.9 cm2. The left ventricular systolic function was preserved and there was mild mitral
stenosis. Coronary angiography showed a left dominant circumflex and atretic left internal mammary artery graft to the
distal left anterior descending artery. LM coronary artery was
widely patent. Transfemoral implantation of a 20-mm
Edwards Sapien 3 valve inside 21-mm Mitroflow bioprosthesis under the guidance of transesophageal echocardiography
was initially uneventful (Figure 1). Postprocedure, the patient
was extubated in the catheterization suite, during which she
complained of chest pain. Deep ST-segment depression was
noted on a cardiac monitor and an electrocardiogram (ECG)
suggesting possible anterolateral and inferior subendocardial
ischemia. Stat echocardiography showed a mild reduction in
left ventricular systolic function, but no evidence of pericardial effusion, aortic root dissection, or aortic hematoma.
Urgent coronary angiography revealed Mitroflow leaflet
overriding the LM ostium with poor flow in the left coronary
artery (Figure 2). Upper cells of Edwards Sapien 3 valve
could not be crossed because of obstruction by the prosthetic
valve leaflet, so the LM artery was wired and ballooned
behind the Sapien 3 valve (Figure 3). A channel (“neo left
main”) was created alongside the Edwards Sapien 3 valve
extending from mid-LM artery to the upper margin of the
Edwards Sapien 3 valve. The first stent was compressed by
the Edwards Sapien 3 valve and aorta. Two bare metal stents
were needed to scaffold the Edwards Sapien 3 valve efficiently and to provide a new LM coronary artery channel
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Figure 2. Coronary angiography showing Mitroflow leaflet
overriding the left main coronary ostium with poor flow in left
coronary artery.

Figure 3. Insertion of left main coronary wire and balloon
behind the Sapien 3 valve following inability to cross the upper
cells of Edwards Sapien 3 valve due to obstruction by the
Mitroflow bioprosthetic valve leaflet.

(Figure 4). Following the intervention, the patient’s hemodynamics and ECG changes improved. Repeat echocardiography demonstrated normal ejection fraction and normal valve
function. The patient was discharged on postoperative day 4.

Discussion
Coronary obstruction following VIV TAVR procedure is
uncommon with an overall reported incidence of ≤3.5%
across different VIV registries.3,11,12 This in addition to the
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Figure 4. Two bare metal stents effectively scaffolding the
Edwards Sapien 3 valve and providing a new channel towards the
left main coronary artery.

data from case reports and case series have documented
instances of coronary obstruction with the use of various
transcatheter heart valves (THVs) on stented or stentless surgical bioprosthesis valves3,11-17 (Table 1). However, no data
exist on incidence or management of coronary obstruction in
patients undergoing Edwards Sapien 3 THV for the failed
Mitroflow surgical bioprosthesis. Mechanical obstruction of
LM coronary ostium is more common than right ostium, and
acute hemodynamic compromise is reported more often than
delayed presentation following TAVR.3,13-19 This case highlights the importance of management of coronary obstruction in the setting of VIV utilizing Edwards Sapien 3 THV
for the failed Mitroflow bioprosthesis with the insertion of
stents between the surgical valve leaflets and aorta creating a
channel (“neo left main”) such that the flow through coronary ostium into the coronary system can be regained.
Risk of coronary obstruction following VIV procedure
depends on various factors such as the type of bioprosthetic
valve used during the initial valve surgery (ie, stentless vs
internally stented surgical valves, supra-annular position,
high-leaflet profile, and bulky leaflets), anatomical factors
(ie, low-lying coronary ostia, narrow sinotubular junction,
narrow sinuses of Valsalva, and previous root repair) as well
as THV factors (ie, extended sealing cuff and high implantation).5 According to the literature, it has been postulated that
the stentless or internally stented valves such as Mitroflow
may pose a higher risk of coronary obstruction following
VIV procedure. This is likely due to the extension of the leaflets of the Mitroflow valve in an outward direction in tubular
fashion beyond the surgical device frame such that the leaflets then compress onto the aortic walls and thus obstructing
coronary blood flow. Although in registries where Mitroflow

was one of the most commonly used valves, in majority of
cases the VIV procedures were uneventful.5 However, in
comparison to the stented valves, Mitroflow was associated
with significantly higher proportion of mortality associated
with the coronary obstruction (7.7% out of total of 57.1%
mortality rate) following VIV procedure in Global VIV
Registry (P = .049).6 Suggested strategies for reduction of
coronary obstruction include an initial evaluation with computed tomography, transthoracic and transesophageal echocardiography, and/or fluoroscopy/angiography for precise
placement.5,6 If VIV is considered an optimal approach in
patients with high risk for surgery, then during the procedure
it is recommended to perform balloon valvuloplasty initially.
If after valvuloplasty a patient remains hemodynamically
stable and risk of coronary obstruction seems higher, then it
is recommended to preemptively protect the coronary by
putting a wire and a stent.5,20 Once the valve is deployed, it is
recommended to take several angiographic pictures from different directions during withdrawal of guide, such that the
assessment of coronary obstruction before removal of wire
and stent can be made. Since the late presentation of coronary obstruction is possible, postprocedure ECG, echocardiography, and signs and symptoms of myocardial ischemia
evaluation are warranted.5 In this report, the patient developed coronary obstruction even after a thorough assessment
of the risk of obstruction. However, there are operative factors that could have contributed to the coronary obstruction
and with the use of procedural steps as highlighted above
could have provided smoother management in this instance.
First, the implantation of SAPIEN 3 valve inside a Mitroflow
prosthesis was high (Figures 2-4). Second, it would have
been the more straightforward management of coronary
obstruction if we had wired the coronary ostium before the
implantation of the SAPIEN 3 valve. We did not anticipate
this problem beforehand and hence did not wire the ostium.
In situations such as this, where it is difficult to approach
coronary ostium post VIV, creating a channel between
obstructing and bulkier Mitroflow leaflets and aorta could be
considered such that deployment of stent in coronary ostium
becomes easier and such a channel could potentially be kept
open from the upper aspect of the Mitroflow leaflets and
Edwards Sapien 3 valve to the LM coronary ostium.

Conclusion
Coronary obstruction is a rare complication of VIV procedure when an Edward Sapien 3 valve is used in the setting of
degenerated Mitroflow bioprosthesis. Careful assessment of
the anatomical relationship between coronary ostia and
Mitroflow bioprosthesis using either computed tomography
and/or transesophageal echocardiography is important.
Placement of stents between bioprosthetic valve leaflets and
aorta may be needed to create a channel between the upper
margins of Edward Sapien 3 valve and LM artery in the setting of LM ostium obstruction.
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PARTNER 2
VIV registry

Type of Study

1

Allende et al,16 Case report
2014
Dvir et al,3 2012 Global VIV
registry
1

1

1

Left main

Left and right main

Left and right main

Left main

Not available

Not available

2

2

Left and right main
(subject 1); left
main (subject 2)

Type of VIV THV

Regurgitation: 68/202
(34)
Mixed: 49/202 (24)
Mixed

Mitroflow (stented)

Stentless: 47 (23)

Stented: 155 (77)

Freestyle (stentless)

Sorin Freedom Solo
(stentless)
St. Jude Toronto
(stentless)

Sorin Freedom Solo
(stentless)

23-mm Edwards Sapien
(subject 1) and 26-mm
CoreValve (subject 2)

26-mm CoreValve and
23-mm Sapien XT

23-mm Sapien XT

29-mm CoreValve
Evolut-R
29-mm CoreValve

26-mm CoreValve (n =
1); 23-mm Evolut-R
(n = 3); 23-mm Lotus
(n = 1)

Stentless: 20/162 (12)

Regurgitation: 52/162
(32)
Mixed: 54/162 (33)
Stenosis: 5 (83)

Mixed: 76/357 (21)
Stenosis: 56/162 (35)

Stentless or
homograft:22/365
(6)
Unknown: 6/365 (2)
Stented: 142/162 (88) 23-, 25-, or 26- mm
Portico, or CoreValve

Regurgitation: 84/357
(24)

Resolute stent 4.0 × 15 mm Regurgitation
in left main, and 3.5 × 18
mm in right main artery
Promus element 4.0 × 12 mm Mixed
stent
Not available
Stenosis: 85/202 (42)

CABG and sternotomy
(subject 1); inoperable
(subject 2)

Type of Surgical
Bioprosthesis, n (%)

Stenosis: 197/357 (55) Stented: 337/365 (92) 23- or 26- mm Sapien XT

Subject 2: CoreValve snaring Regurgitation: 1 (17)
into aorta
Removal of Lotus valve
Regurgitation

Subject 1: balloon
aortography and repeat
surgery

Not available

Not available

Treatment of Coronary
Obstruction

Degeneration
Mode (Stenosis,
Regurgitation, Mixed),
n (%)

Abbreviations: VIV, valve-in-valve; THV, transcatheter heart valve; PARTNER 2, placement of aortic transcatheter valves 2; CABG, coronary artery bypass grafting.

Case series

1

Case report

Fabris et al,15
2016

Gurvich et al,17
2011

1

Praz et al,14 2016 Case report

2

2 (1.9);
CoreValve

3 (0.8)

Branch of Coronary
Ostial Obstruction

Left main
202; CoreValve (n = 7 (3.5); 4
CoreValve and
124) and Sapien XT
3 Sapien XT
(n = 78)

6

162; Portico (n = 54)
and CoreValve
(n = 108)

365

Number of Subjects

Cokburn et al,13 Case series
2017

Alnasser et al,12 VIV
2017
international
data registry

Webb et al,
2017

11

Author, Year

Number of
Subjects With
Coronary
Obstruction,
n (%)

Table 1. Coronary Obstruction Following Valve-in-Valve Transcatheter Aortic Valve Replacement.
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